Basic Information
| LncRNA/CircRNA Name | MIR503HG |
| Synonyms | NA |
| Region | GRCh38_X:134543337-134546632 |
| Ensemble | ENSG00000223749 |
| Refseq | NR_024607 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical squamous cell carcinoma |
| ICD-0-3 | C53 |
| Methods | qPCR, Western blot etc |
| Sample | cell lines(SiHa) |
| Expression Pattern | down-regulated |
| Function Description | In this study, we observed that levels of miR503HG in plasma were significantly lower in CSCC patients than in healthy participants. The cisplatin-based treatment further downregulated miR503HG in both patients and CSCC cells. MiR503HG overexpression in CSCC cells led to the suppression of miR-155 and elevation of Caspase-3, acting as the downstream target of miR-155. Cell apoptosis analysis showed that miR503HG and Caspase-3 overexpression led to an increased cell apoptosis rate under Cisplatin treatment. |
| Pubmed ID | 32184661 |
| Year | 2020 |
| Title | LncRNA miR503HG Regulates the Drug Resistance of Recurrent Cervical Squamous Cell Carcinoma Cells by Regulating miR-155/Caspase-3 |
External Links
| Links for MIR503HG | GenBank HGNC NONCODE |
| Links for cervical squamous cell carcinoma | OMIM COSMIC |